FDA Drug Label Rule Is “In Its Final Stages,” Crawford Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting Commissioner Crawford has given FDA staff “one more week” to work out final language of the revised drug labeling format rule.
You may also be interested in...
Labeling Rule Could Strike Implied Indications, GSK Exec Says
The "Highlights" section of the revised labeling will be the biggest challenge due to its size restriction, GSK Strategic Product Labeling Group Director Hardy says. She recommends that firms prepare to rework their labels but cautioned against investing a lot of time anticipating a rule change that might not happen.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.